Healthcare providers
Science-driven innovation for better patient outcomes
At Xenon, we are focused on developing medicines that modulate ion channels to address neurological and psychiatric disorders. Our lead investigational candidate, azetukalner, is a Kv7 potassium channel opener in late-stage clinical development for multiple epilepsy indications (focal and generalized seizures) and depression (major depressive disorder and bipolar depression). Our early-stage pipeline leverages this same ion channel expertise to target chronic and acute pain and severe genetically defined epilepsies, like Dravet syndrome.
Visit with us at the American Academy of Neurology (AAN) Annual Meeting
Chicago, IL
April 18-22, 2026
The AAN Annual Meeting convenes neurologists, neuroscience professionals, advocates, industry partners, and other specialists dedicated to advancing neurological care
Exhibit Hall
Sunday, April 19, 2026 | 11:30 am CT - Wednesday, April 22, 2026 | 4 pm CT
Booth #2330
Efficacy & Safety Data for Azetukalner in Focal Onset Seizures
Oral and Poster Presentation #007
Results from the Phase 3 X-TOLE2 Study Evaluating Azetukalner, a Novel, Potent KV7 Channel Opener, in Adults With Focal Onset Seizures (FOS)
Session: LS1 - Late-breaking Science 1
Sunday, April 19,
5:36 pm-5:42 pm CT;
Poster presentation to follow from 5:54-6:15 pm CT
Poster Presentation #10-001
Azetukalner, a Novel, Potent KV7 Channel Opener, in Adults With Focal Epilepsy: ≥48-Month Interim Analysis of the Ongoing 7-Year X-TOLE Open-Label Extension
Session: P11 – Poster Session 11
Wednesday, April 22,
11:45-12:45 pm CT
Real World Epilepsy Data
Poster Presentation #11-007
Treatment Experiences with Anti-seizure Medications (ASMs): Patient–Clinician Perspectives on Titration Burden, Quality of Life, and No‑Titration Options
Session: P3 – Poster Session 3
Sunday, April 19,
5:00-6:00 pm CT
Oral Presentation #002
Examining the Impact of Comorbid Depression on Healthcare Utilization, Cost, and Outcomes in Patients with Newly Diagnosed Epilepsy in the US
Session: S41 – Epilepsy: Public Health and Epidemiology
Wednesday, April 22,
1:12-1:24 pm CT
Early-Stage Pipeline Data
Oral Presentation #004
Selective Potentiation of NaV1.1 Channels by Small Molecule XPC-837 in Dravet Mice Suppresses Spontaneous Seizures, Prevents SUDEP, and Increases Long Term Potentiation
Session: S19 – Emerging Therapies in Child Neurology
Monday, April 20,
4:06-4:18 pm CT
Featured publications
Efficacy and Safety of XEN1101, a Novel Potassium Channel Opener, in Adults With Focal Epilepsy: A Phase 2b Randomized Clinical Trial
JAMA NeurologyEfficacy and Safety of XEN1101, a Novel Potassium Channel Opener, in Adults With Focal Epilepsy: <span>A Phase 2b Randomized Clinical Trial</span>Interim Analysis of the Long-term Efficacy and Safety of Azetukalner in an Ongoing Open-label Extension Study Following a Phase 2b Clinical Trial (X-TOLE) in Adults with Focal Epilepsy
Epilepsia OpenInterim Analysis of the Long-term Efficacy and Safety of Azetukalner in an Ongoing Open-label Extension Study Following a Phase 2b Clinical Trial (X-TOLE) in Adults with Focal EpilepsyAzetukalner, a Novel Kv7 Potassium Channel Opener, in Adults With Major Depressive Disorder: A Randomized Clinical Trial
JAMA Network OpenAzetukalner, a Novel Kv7 Potassium Channel Opener, in Adults With Major Depressive Disorder: <span>A Randomized Clinical Trial</span>
Meet with your MSL
To meet a Medical Science Liaison (MSL) in your region, please fill out this form.
Spotlight on epilepsy
Hear from leading voices in the epilepsy field as they discuss current treatments and opportunities to improve patient care
Video Name
Clinical trials
We are actively enrolling patients in late-stage clinical trials across a spectrum of challenging neurological and psychiatric disorders, building upon promising Phase 2 data. This pivotal studies include:
Read our brochure to learn more about our Phase 3 clinical trials in epilepsy
Expanded access
Xenon Pharmaceuticals is committed to developing innovative, safe, and effective therapeutics to improve the lives of patients with neurological disorders, and we recognize the value of collaborating with patients, families, advocacy organizations, physicians and other healthcare professionals, researchers, and regulatory authorities to accomplish this goal.
We understand that patients, families, and physicians may be interested in accessing Xenon’s investigational drugs prior to regulatory approval through an expanded access program (sometimes referred to as “compassionate use program”). Expanded access programs allow patients with serious or immediately life‑threatening diseases, who have exhausted all other treatment options, to access an investigational drug outside of a clinical trial and prior to regulatory approval.
Xenon does not currently have an expanded access program that makes our investigational drugs available to patients other than by participating in one of our clinical trials. Clinical trials are controlled studies in humans designed to establish whether an investigational drug is safe and effective. Xenon believes clinical trials are the most appropriate way to efficiently collect all data necessary to seek regulatory approvals. At this time, Xenon does not have sufficient information about the potential risks and benefits of our investigational drugs to ensure that patient access outside the regulated clinical trial process does not delay or compromise our clinical trials and, ultimately, broad availability to the entire patient community.
Physicians, patients, and caregivers interested in learning more about Xenon’s ongoing clinical trials can find additional information at ClinicalTrials.gov.
Xenon may revise this policy at any time. If you have additional questions, please contact us at medicalinformation@xenon-pharma.com.